Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Perrigo Company    PRGO

 SummaryNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Financials ($)
Sales 2017 4 769 M
EBIT 2017 912 M
Net income 2017 289 M
Debt 2017 2 653 M
Yield 2017 0,88%
Sales 2018 4 925 M
EBIT 2018 991 M
Net income 2018 478 M
Debt 2018 2 166 M
Yield 2018 0,92%
P/E ratio 2017 38,02
P/E ratio 2018 23,39
EV / Sales2017 2,85x
EV / Sales2018 2,66x
Capitalization 10 933 M
More Financials
Company
Perrigo Co. Plc engages in the production of over-the-counter consumer goods and specialty pharmaceutical products.It operates through the following segments: Consumer Healthcare (CHC), Branded Consumer Healthcare (BCH), Prescription Pharmaceuticals, and Specialty Sciences.The CHC segment includes... 
Sector
Pharmaceuticals
Calendar
08/09Earnings Release
More about the company
Surperformance© ratings of Perrigo Company
Trading Rating : Investor Rating :
More Ratings
Latest news on PERRIGO COMPANY
07/24 PERRIGO CO PLC : Material Modification to Rights of Security Holders, Submission..
07/21 PERRIGO : Change in Directors or Principal Officers, Financial Statements and Ex..
07/20 PERRIGO : Gets FDA Approval for Generic Topical Gel
07/19 PERRIGO : Announces FDA Final Approval For Its AB Rated Generic Version Of DermO..
07/17 PERRIGO : Confirms Patent Challenge For Generic Version Of Soolantra® Cream, 1%
07/17 PERRIGO : Announces FDA Final Approval For Its First-To-File Ab Rated Generic Ve..
07/17 PERRIGO : Announces Settlement Of Generic Version Of Dymista® Nasal Spray Patent..
07/13 PERRIGO : Launches The Generic Version Of Axiron® Topical Solution
07/11 PERRIGO : Global Analgesics Market 2017 - Crown Pharmaceuticals, Perrigo Company..
07/06DJJEFF FETTIG : For CEOs, High Pay, Higher Anxiety -- WSJ
More news
Sector news : Pharmaceuticals - NEC
09:53a AstraZeneca shares plunge 15 percent as lung cancer study fails
09:41aDJASTRAZENECA : Faces Major Setback Over Cancer Drugs
09:35a AstraZeneca slump dominates European open on busy earnings day
08:48aDJGLAXOSMITHKLINE : Glaxo Hones R&D Focus to 4 Diseases -- WSJ
08:39aDJASTRAZENECA : Swings to $477 Million Net Profit in 2Q
More sector news : Pharmaceuticals - NEC
Income Statement Evolution
Consensus
 
Mean consensus HOLD
Number of Analysts 17
Average target price 76,0 $
Spread / Average Target -0,31%
EPS Revisions
Managers
NameTitle
John T. Hendrickson Chief Executive Officer & Director
Mary Lauren Brlas Chairman
Ron L. Winowiecki Chief Financial Officer
Thomas Farrington Chief Information Officer & Executive VP
Grainne Quinn Chief Medical Officer & Executive Vice President
Sector and Competitors
1st jan.Capitalization (M$)
PERRIGO COMPANY10 933
JOHNSON & JOHNSON14.47%355 263
NOVARTIS7.69%220 651
ROCHE HOLDING LTD.4.08%220 599
PFIZER1.91%197 115
MERCK AND COMPANY4.98%170 565